BioMarin’s Gene Therapy for Hemophilia A Remains on Track for US Approval

BioMarin’s Gene Therapy for Hemophilia A Remains on Track for US Approval
4.2
(5)

Despite the COVID-19 pandemic, BioMarin Pharmaceutical‘s application to the U.S. Food and Drug Administration (FDA) seeking approval of valoctocogene roxaparvovec, an experimental gene therapy for adults with severe hemophilia A, remains on track.

During a conference call, the company also said that if approved, the therapy will be marketed under the brand name Roctavian. (It was previously branded Valrox.)

BioMarin’s biologics license application to the FDA is under priority review. The agency is expected to announce a final decision by Aug. 21

“This milestone represents a tremendous achievement for BioMarin, but the potential approval of the first gene therapy in any type of hemophilia is an even greater triumph for the hemophilia community. They have been waiting decades for this groundbreaking advancement and we are honored to be on this journey together,” Jean-Jacques Bienaimé, chairman and CEO of BioMarin, said in a press release.

“With an approval decision for valoctocogene roxaparvovec expected later this year, our commercial team prepares eagerly to launch what we believe is the most innovative product yet for people with bleeding disorders,” Bienaimé added.

The company also has submitted a similar request to the European Medicines Agency (EMA) in the form of a marketing authorization application. The European Union agency has been reviewing BioMarin’s application under accelerated assessment since January.

However, the company expects EMA’s review process to revert back to a standard procedure. Along with a delay of at least three months due to the COVID-19 pandemic, BioMarin ultimately anticipates an opinion from the Committee for Medicinal Products for Human Use (CHMP) — a branch of EMA whose recommendations on whether to approve therapies are usually  followed by the agency — no sooner than late this year or early 2021.

On behalf of the EMA, the Health Products Regulatory Authority of Ireland has already conducted a pre-approval inspection of BioMarin’s manufacturing facility. A similar inspection by the FDA is expected by the end of June.

Formerly known as BMN 270, the gene therapy uses harmless adeno-associated virus (AAV) vectors to deliver a functional copy of factor VIII — the blood-clotting protein missing or defective in people with hemophilia A — to patients’ cells.

Both U.S. and EU applications were based on updated data from a Phase 1/2 trial (NCT02576795) and on an early analysis of the ongoing Phase 3 GENEr8-1 study (NCT03370913).

Three-year results from the Phase 1/2 trial showed that a single administration of the gene therapy at a dose of 6e13 vg/kg (vector genomes per kilogram) markedly reduced the number of bleeding episodes and the need for factor VIII infusions in a small group of adults with severe hemophilia A.

Updated four-year findings from patients who received this dose and three-year data from those given the lower 4e13 vg/kg dose are expected soon.

The company has already dosed the 134 patients currently participating in GENEr8-1, and expects to announce one-year data in the first quarter of 2021.

Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.
Total Posts: 46

José holds a PhD in Neuroscience from Universidade of Porto, in Portugal. He has also studied Biochemistry at Universidade do Porto and was a postdoctoral associate at Weill Cornell Medicine, in New York, and at The University of Western Ontario in London, Ontario, Canada. His work has ranged from the association of central cardiovascular and pain control to the neurobiological basis of hypertension, and the molecular pathways driving Alzheimer’s disease.

×
Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.
Latest Posts
  • Roctavian
  • FDA on Roctavian
  • BAY 2599023
  • Eloctate, #ISTH2020

How useful was this post?

Click on a star to rate it!

Average rating 4.2 / 5. Vote count: 5

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?

Pin It on Pinterest

Share This